SUPPLEMENTARY TABLE AUTHOR YEAR AGE SEX STAGE HISTOLOGIC HL

Author

Year

Age

Sex

Stage, Histologic HL Type

Viruses

Bilirubin on admission (Direct) (mg/d)

Treatment

Outcome/ Cause of death

1

Our patient

2020

31

F

N.S. IIA

EBV, CMV

21.5 (13.7)

UDCA, Dexamethasone, ABVD (6 cycles)

Remission

2

Anugwom C. et al [7]

2020

27

F

6 (5.4)

1) Radiotherapy, Dexamethazone, Rituximab, Gemcitabine and Cisplatin 2) ABVD

Remission

3

Raquel D.Greca et al [10]

2019

25

F

N.S.

19.6 (14)

Prednisone, UDCA , AB (1 cycle), ABVD (5 cycles)

Slight clinical improvement

4

Fong Min et al [21]

2019

39

F

III

9.88 (8.07)

UDCA, Prednisone (cycles 1-7) CP (almost full dose, cycles 1-6) Procarbazine ( cycles 3-6) Brentuximab (cycles 4-6)

Remission

5

Das Aniban et al [22]

2018

7

M

IVB

CMV

6 (3.4)

Prednisolone Bleomycin Darcarbazine (2 weeks), DHAP ( 3 cycles)

Death/Hepatic failure

6

Bakhit Mena et al [11,23]

2016

25

M

IIB

6.2 (3.9)

Nitrogen Mustard , Corticosteroids , Radiotherapy Ultimately Gemcitabine/Oxaliplatin

Remission

7

Bakhit Mena et al [23]

2016

41

F

N.S. IIA

Increased

UDCA, Rifampin, DHAP (50% reduced cytarabine), Radiotherapy

Death/ Unknown causes

8

Sathyanarayanan V. et al [18]

2016

39

M

N.S. IIIB

10

Mechlorethamine ( 2 doses), AVD (Cycle 1A 50% dose reduction, Cycle 1B 25% dose reduction, 5 Cycles full)

Remission

9

Yeh P. et al [24]

2014

75

M

M.C.

HAV, HBV, CMV, EBV

17.36

UDCA, ABVD

Death/Sepsis

10

Rota Scalabrini et al [1]

2014

42

F

N.S. IIB

18.3 (15.3)

UDCA, Prednisone, ABVD (6 cycles)

Remission

11

Hallen Karin et al [20]

2014

N.M.

M

N.S. IIB

HBV,CMV

6

Rituximab (weekly x 4), BEACOPP -Etoposide: 50% dose (5 cycles), Doxorubicine: 60% dose for cycle 1 and 70% until the end, CP: 50% dose for cycle 1 and 70% until the end

Remission

12

Nader K. et al [25]

2013

64

F

N.S

45

Gemcitabine, Dexamethasone, Cisplatin

Death/Hepatic failure, sepsis

13

Aleem A. et al [26]

2013

33

M

N.S. IIIB

5.14(4.32)

ABVD (1 cycle, 30% reduced dose), ESHAP (2 cycles, 50% increase in methylprednisolone in the latter)

Death/Hepatic failure

14

Amer S. et al [8]

2013

40

M

III

4.2 (2.5)

ABVD

Remission

15

Wong Km. et al [13]

2013

38

M

M.C. IIA

14.8 (9.39)

1) ABVD (4 cycles) 2) Autologous
hematopoietic cell transplantation with BEAM

Remission

16

Umit H. [27]

2009

45

M

N.S.

HBV

20.3 (20)

ABVD (8 cycles) + 24 sessions of radiotherapy when HL presented 6 months prior Prednisolone after the diagnosis of VBDS

Remission

17

Pass AK. et al [9]

2008

10

M

M.C. IIIB

EBV

3.8

1) Nitrogen mustard, Prednisone, 2) Stanford V (initially
with 50% dose reduction of Adriamycin and vinblastine, 25%
dose reduction of vincristine, and full doses of bleomycin and VP-16) 3) rituximab (total of 4 doses), 4) IFRT

Death/ Aspiration

18

Pass AK. Et al [9]

2008

12

M

M.C. , N.S. IIIB

EBV

10.8 (6)

1) MOPP-ABV [nitrogen mustard, procarbazine (for 7 days),
prednisone (for 14 days), 50% dose adriamycin
and 50% dose vinblastine
and bleomycin, 2) 75% dose adriamycin and 75% dose vinblastine (cycle 4) and 100% (cycles 5 and 6), 3) IFRT

Intensifying VBDS/awaiting transplantation

19

Leeuwenburgh et al [28]

2008

17

M

N.S. IIIB

EBV

27.65

1) MOPP (2 courses), 2)50% reduced dose P(V)AG, 3) full dose PVAG (6 courses)

Remission

20

DeBenedet AT. et al [5]

2008

39

M

N.S. IIIA

29.5 (14.4)

Intravenous nitrogen mustard and dexamethasone the first and eighth days of each month and oral dexamethasone daily (for 5 months)

Death/ Unknown causes

21

Ballonoff A. et al [4]

2008

22

M

N.S. IIA

26 (16)

1) Cyclophosphamide, dexamethasone, oral
prednisone, radiation, 2) Radiation alone, 3) Azathioprine, prednisone

Remission

22

Schmitt A. et al [29]

2006

46

M

IIIA

12.7 (7.7)

Empirical use of corticosteroids

Death/Sepsis

23

Han WS. et al [30]

2005

45

M

ΙΙΑ

Radiotherapy

Recurrent HL

24

Córdoba Iturriagagaitia A. et al [31]

2005

17

M

N.S. II

20

Bleomycin, cyclophosphamide, dacarbazine, methylprednisolone (8 cycles)

Remission

25

Guliter S. et al [32]

2004

46

N.M.

ΙΙΙΒ

15.55

Chemotherapy

Death/Sepsis

26

Kömürcü S. et al [33]

2002

23

M

M.C. IIIB

10.1 (4.8)

1) ABVD (6 cycles), 2) ABVD-MOPP (8 cycles), 3) DHAP (2 cycles), 3) Cyclophosphamide, melphalan, cytosine arabinoside, and etoposide with autologous PBSCT

Death/Hepatic failure

27

Ripoll C. et al [34]

2002

28

F

N.S. IIA

HAV

32.8

1) C-MOPP [(cyclophosphamide, vincristine, procarbazine and prednisone) (2 cycles)], 2) Radiotherapy

Death/Hepatic failure

28

Ripoll C. et al [34]

2002

23

M

N.S. IIA

26.9

1) C-MOPP [(cyclophosphamide, vincristine, procarbazine and prednisone) (1 cycle)], 2) ABVD (1 cycle), 3) Radiotherapy, 4) UDCA and cholestyramine, 5) ABVD

Remission

29

Ozkan A. et al [35]

2001

3.5

M

N.S. IIIB

6.14

ABVD (1 cycle), Prednisolone, IV Immunoglobulin, UDCA

Death/Hepatic failure

30

Allory Y. [36]

2000

54

M

IIIB

2.98

Chemotherapy

Remission

31

Rossini MS. et al [12]

2000

38

M

M.C.

33.5 (22.7)

MOPP-ABV (four cycles), high dose Cyclophosphamide, Etoposide

Death/Hepatic failure

32

Yusuf MA. [37]

2000

5

M

IB

Corticosteroids and Chemotherapy

Death/ Hepatic failure

33

De Medeiros BC. et al [38]

1998

27

F

M.C.

23.4 (18.5)

MOPP

Death/Hepatic failure

34

De Medeiros BC. et al [38]

1998

50

F

N.S.

21.7 (16.3)

MOPP/ABV

Remission

35

Crosbie OM. et al [39]

1997

21

F

IIIB

14.3

UDCA, mustine Oncovin Procarbazine Prednisolone Monthly transfusions

Remission

36

Gottrand F. et al [19]

1997

3.5

M

M.C. II

HAV

50

VEBP(3 cycles), ABVP(2 cycles), Radiotherapy

Death/Hepatic failure

37

Hubscher SG. et al [3]

1993

26

M

N.S.

11.7

LOPP/EVA(1 cycle) EVAP (1 cycle) LOPP (1 cycle) miniBEAM (1 cycle)

Death/Pneumonia

38

Hubscher SG. et al [3]

1993

44

M

I

17.5

LOPP (1 cycle)

Death/Sepsis

39

Hubscher SG. et al [3]

1993

37

F

N.S.

LOPP/EVA(1 cycle) Ketoconazole

Death/ Kidney and respiratory failure

NOT CONFIRMED CASES

Author

Year

HL Treatment

Liver Biopsy

1

Barta SK. [40]

2006

YES

IC

2

Liangpunsakul S. [41]

2002

YES

Cholestatic hepatitis

3

Dourakis SP. [42]

1999

YES

Hepatocellural necrosis

4

Yalçin S. [43]

1999

NO

IC

5

Yalçin S. [43]

1999

YES

IC

6

Warner AS. [44]

1994

YES

IC

7

Jansen PLM. [45]

1994

YES

IC

8

Birrer MJ. [46]

1986

YES

IC

9

Lieberman DA. [47]

1986

NO

IC

10

Trewby PN. [48]

1979

YES

IC

11

Trewby PN. [48]

1979

NO

Mild portal hepatitis

12

Trewby PN. [48]

1979

YES

Lymphoma infiltration

13

Trewby PN. [48]

1979

NO

Lymphoma infiltration

14

Trewby PN. [48]

1979

YES

Mixed inflammatory and atypical histiocytes 

15

Trewby PN. [48]

1979

YES

IC

16

Piken EP. [49]

1979

YES

IC

17

Perera DR. [50]

1974

YES

IC

18

Perera DR. [50]

1974

YES

IC

19

Perera DR. [50]

1974

YES

IC

20

Groth C. [51]

1972

YES

IC

21

Juniper K. [52]

1963

YES

IC

22

Bouroncle B. [2]

1962

YES

IC

23

Bouroncle B. [2]

1962

YES

IC